Asset Details
Do you wish to reserve the book?
Expert consensus recommendations on the daily clinical use of pembrolizumab for early triple-negative breast cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Expert consensus recommendations on the daily clinical use of pembrolizumab for early triple-negative breast cancer
Do you wish to request the book?
Expert consensus recommendations on the daily clinical use of pembrolizumab for early triple-negative breast cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Expert consensus recommendations on the daily clinical use of pembrolizumab for early triple-negative breast cancer
2025
Overview
Neoadjuvant chemotherapy is a standard treatment for triple-negative breast cancer (TNBC) at an early stage. Given that pathological complete response is strongly associated with long-term clinical and survival benefits, the selection of appropriate treatment before and after surgery could further optimise treatment outcomes. With the emergence of immunotherapy in breast cancer, more combination treatment options are available, such as pembrolizumab, a programmed death receptor 1 inhibitor, which is approved for the perioperative treatment of stage II and III TNBC. However, the implementation of immunotherapy in perioperative settings for TNBC requires further discussion regarding patient selection and the use of different treatments in conjunction with immunotherapy. The Hong Kong Breast Cancer Foundation convened a multidisciplinary consensus panel consisting of surgeons, clinical oncologists, and medical oncologists to initiate this discussion. A modified Delphi panel was conducted, evaluating seven topics and 45 statements covering the workup and perioperative treatment of early-stage TNBC (eTNBC). The consensus statements provide guidance on determining whether a patient with eTNBC is a suitable candidate for neoadjuvant chemotherapy and immunotherapy.
Publisher
Hong Kong Academy of Medicine
Subject
Antibodies, Monoclonal, Humanized - administration & dosage
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Antineoplastic Agents, Immunological - administration & dosage
/ Antineoplastic Agents, Immunological - therapeutic use
/ Female
/ Humans
/ Ligands
/ Neoadjuvant Therapy - methods
/ Oncology
/ Patients
/ Surgeons
/ Surgery
